Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503259 | 0.90 | NR1H2 (0.42) | RORCNR1H2NR1H3KIF11MCHR1 | |
| SCHEMBL353210 | 0.84 | CNR2 (0.44) | MEN1KMT2AMAPK1TDP1 | |
| SCHEMBL5073885 | 0.82 | RORC (0.47) | RORCNR1H2NR1H3KIF11MCHR1 | |
| SCHEMBL355489 | 0.81 | CNR2 (0.44) | MEN1KMT2ATDP1 | |
| SCHEMBL19503409 | 0.79 | NR1H2 (0.46) | RORCNR1H2NR1H3ARMEN1 | |
| SCHEMBL352863 | 0.79 | KIF11 (0.39) | NR1H2KIF11MCHR1MLYCD | |
| SCHEMBL356422 | 0.79 | CNR2 (0.46) | MAPK1 | |
| SCHEMBL7755356 | 0.78 | NR1H2 (0.54) | NR1H2NR1H3ARMEN1KMT2A | |
| SCHEMBL16746560 | 0.78 | CYP19A1 (0.40) | RORCMEN1KMT2A | |
| SCHEMBL11219468 | 0.76 | S100B (0.51) | ARCYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | RORC 4169/4885NR1H2 1145/4885NR1H3 1383/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | RORC 2774/4885NR1H2 273/4885NR1H3 235/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | RORC 2836/4885NR1H2 284/4885NR1H3 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.